Search

This study aimed to correlate planned dose to the nausea center (NC)—area postrema (AP) and dorsal vagal complex (DVC)—with nausea and vomiting symptoms in oropharyngeal cancer (OPC) patients treated with intensity-modulated radiation therapy (IMRT) without chemotherapy. We also investigated whether it was possible to reduce doses to the NC without significant degradation of the clinically accepted treatment plan. From November 2004 to April 2009, 37 OPC patients were treated with definitive or adjuvant IMRT without chemotherapy. Of these, only 23 patients had restorable plans and were included in this analysis. We contoured the NC with the assistance of an expert, board-certified neuroradiologist. We searched for correlation between the delivered dose to the NC and patient-reported nausea and vomiting during IMRT. We used one-paired two-sample t test assuming equal variances to compare differences in dose to NC between symptomatic and asymptomatic patients. We then replanned each case to determine if reduced dose to the NC could be achieved without compromising coverage to target volumes, increasing unwarranted hotspots, or increasing dose to surrounding critical normal tissues. Acute symptoms of nausea were as follows: grade 0 (n = 6), grade 1 (n = 13), grade 2 (n = 3), and grade 3 (n = 1). Patients with no complaints of nausea had a median dose to the DVC of 34.2 Gy (range 4.6–46.6 Gy) and AP of 32.6 Gy (range 7.0–41.4 Gy), whereas those with any complaints of nausea had a median DVC dose of 40.4 Gy (range 19.3–49.4 Gy) and AP dose of 38.7 Gy (range 16.7–46.8 Gy) (p = 0.04). Acute vomiting was as follows: grade 0 (n = 17), grade 1 (n = 4), grade 2 (n = 1), and grade 3 (n = 1). There was no significant difference in DVC or AP dose among those with and without vomiting symptoms (p = 0.28). Upon replanning of each case to minimize dose to the NC, we were, on average, able to reduce the radiation dose to AP by 18 % and DVC by 17 %, while the average dose variations to the planning target volume (PTV) coverage, brainstem, cord, temporal lobes, and cochlea were never greater than 3 %. Hotspots increased by 2 % for three patients while hotspots for the remaining patients were less than 2 % variation. For OPC cancer patients treated with IMRT without chemotherapy, dose to AP and DVC may be associated with development of nausea. We were able to show that reducing doses substantially to the NC is achievable without significant alteration of the clinically accepted plan and may reduce the incidence and grade of nausea. As symptoms of nausea can be devastating to patients, one can consider routine contouring and constraining of the NC to minimize chances of having this complication.

• Best practice molecular diagnostic reference standards require international collaboration.

A 56-year-old man gave a 6-month history of progressive dyspnoea and orthopnoea. During breathing, his abdominal muscles showed paradoxical movement and he rapidly and reproducibly developed difficulty breathing when lying supine. The most likely explanation was severe weakness or paralysis of both hemidiaphragms. This was confirmed with electrophysiology and ultrasonography. Extensive investigation identified no underlying cause, suggesting this is a case of bilateral isolated phrenic neuropathy. We present a video showing how easily bilateral diaphragmatic palsy can be detected clinically through identifying paradoxical abdominal wall movement.